Inclusion Criteria:

• Subjects must provide written, voluntary informed consent to participate in the study.
• Subjects must be naive to antiretroviral treatment with HIV RNA greater than or equal to 1,000 copies/mL at screening, and in the investigator's opinion, require antiretroviral therapy.
• Subject's vital signs, physical examination and laboratory results do not exhibit evidence of acute illness.
• Subject has not been treated for an active AIDS-defining opportunistic infection within 45 days of initiating study drug. Subjects who are on stable maintenance therapy for an opportunistic infection may be enrolled after consultation with Sponsor.
• Subject does not require and agrees not to take any drugs that are contraindicated or have significant pharmacokinetic interactions with study drugs during the course of the study. Subject agrees not to take any medication during the study, including over-the-counter medicines, vitamins, minerals, herbal preparations, alcohol or recreational drugs, without the knowledge and permission of the principal investigator.
• Female subjects must be either postmenopausal for at least one year, surgically sterile, or must use a non-hormonal method of birth control that is acceptable to both the subject and investigator. All female subjects must have a urine pregnancy test performed at screening visit and on day
• 1/baseline, and results of both tests must be negative. Female subjects may not be breastfeeding.
• Subjects have received no prior treatment with an HIV-1 integrase inhibitor.

Exclusion Criteria:

• Subjects must not have history of an allergic reaction or significant sensitivity to the study drugs.
• Subjects may not have an ongoing history of substance abuse or psychiatric illness that could preclude protocol adherence.
• Subject cannot have resistance to lopinavir/ritonavir, tenofovir or emtricitabine based on the HIV-1 drug resistance genotypic test results at the screening visit.
• Subject may not have significant medical history of concomitant illness or disease that would adversely affect his/her participating in the study.
• Subjects may not have received any investigational drug or investigational vaccine within 30 days prior to study drug administration.
• Subjects may not have any of the following abnormal screening results: Hemoglobin <= 8.0 G/dL, absolute neutrophil count <= 750 cells/mcl/mL, Platelet count <= 50,000 per mL, ALT (SGPT) or AST (SGOT) >= 3.0 x upper limit of normal (ULN), calculated creatinine clearance < 50 mL/min, Hepatitis B surface antigen HBsAG is positive.
• The investigator considers the subject to be an unsuitable candidate for the study.